Formulation demand on the rise

Dalton Pharma Services has added formulation development to its repertoire. The kilo-scale contract manufacturer works in such dosage forms as sterile and non-sterile liquids, solids, semi-solids and lyophilized formulations (small chemical molecules, proteins and peptides, monoclonal antibodies, and high-potency actives).

The formulation services complement the Toronto company's integrated development capabilities for novel drugs, according to an announcement. The company boasts advanced capsule-filling technology, it says, in addition to analytical services expanded to encompass formulation development. Dissolution testing and particle-size-distribution testing are now available.

Formulators appear to be finding work, despite market pessism. In the last quarter alone, OctoPlus announced that it had landed a "significant" formulation development and clinical manufacturing contract; CoreRx cut the ribbon on a facility expansion to beef up capacity; and Xcelience named a team leader for its formulation development unit.

And biochemical supplier Bachem has been tapped by ImmuneRegen BioSciences to produce the active pharmaceutical ingredient for the biotech's Homspera drug substance. The contract calls for production of quantities to support formulation, pre-clinical studies and several Phase I studies.

- here's the Dalton Pharma release
- see the ImmuneRegen announcement

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.